|
28 Sep 2023 |
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
|
|
28 Sep 2023 |
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
|
|
28 Sep 2023 |
Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
|
|
28 Sep 2023 |
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
|
|
27 Sep 2023 |
c-Met: a well-suited target for payload delivery by antibodies – a pipeline review
|
|
27 Sep 2023 |
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis
|
|
27 Sep 2023 |
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
|
|
27 Sep 2023 |
Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis
|
|
27 Sep 2023 |
Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia
|
|
26 Sep 2023 |
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
|
|
26 Sep 2023 |
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
|
|
26 Sep 2023 |
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
|
|
26 Sep 2023 |
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
|
|
26 Sep 2023 |
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
|
|
25 Sep 2023 |
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
|
|
23 Sep 2023 |
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
|
|
22 Sep 2023 |
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
|
|
22 Sep 2023 |
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
|
|
22 Sep 2023 |
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
|
|
22 Sep 2023 |
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
|
|
21 Sep 2023 |
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
|
|
21 Sep 2023 |
Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission
|
|
21 Sep 2023 |
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
|
|
20 Sep 2023 |
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
|
|
20 Sep 2023 |
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
|
